Liquidia Corporation (LQDA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance and optimistic future guidance. YUTREPIA's market share increased significantly, and management is confident in achieving a $1 billion revenue target by 2027. Product differentiation and strategic clinical trials are expected to drive growth. Despite some vague responses, the overall sentiment is positive, with no major concerns raised. The lack of market cap data prevents a more nuanced prediction, but the positive outlook suggests a stock price increase in the short term.
Key Financial Performance
Net Product Sales for 2025 $148.3 million, including $90.1 million in the fourth quarter, representing 74% growth in net product sales over the third quarter, 2025. The growth is attributed to sustained patient growth and retention and disciplined execution.
Non-GAAP Adjusted EBITDA for Q4 2025 $27.3 million, marking the second consecutive quarter of increasing profitability. This reflects sustained patient growth and retention.
Net Income for Q4 2025 $14.6 million, indicating profitability driven by increased revenue and disciplined execution.
Cash and Cash Equivalents at Year-End 2025 $190.7 million, with $33 million of positive cash flow generated in the fourth quarter alone. This reflects the company's transition to a cash-generating growth engine.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
YUTREPIA launch and performance: YUTREPIA was launched and scaled to profitability within 120 days. It is recognized as one of the top specialty drug launches in the past 5 years, with benefits like deep-lung delivery, low-effort device, and wide dose range. Over 3,600 unique patient referrals and therapy shipped for more than 2,900 patients since launch.
Clinical exploration of YUTREPIA and L606: New studies will be initiated to transition patients from oral and inhaled prostacyclin therapies, explore new combinations like adjunctive studies with sotatercept, and expand into additional disease areas such as systemic sclerosis-associated Raynaud's phenomenon and PH-COPD.
Market share growth: YUTREPIA is capturing a disproportionate number of new patient starts for inhaled prostacyclins, with a rising market share. New patient prescriptions are evenly split between PAH and PH-ILD indications.
Financial performance: YUTREPIA generated $148.3 million in net product sales in 2025, including $90.1 million in Q4, marking a 74% growth over Q3. The company achieved $27.3 million in non-GAAP adjusted EBITDA and $14.6 million in net income in Q4. Ended the year with $190.7 million in cash and cash equivalents.
Expansion strategy: The company plans to fund clinical evidence expansion through operational cash flow, aiming to grow the value of the franchise and achieve a $1 billion franchise by 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The discussion includes forward-looking statements subject to risks and uncertainties, which may cause actual results to differ materially. This indicates potential regulatory or compliance risks that could impact operations or financial outcomes.
Market Competition: The company acknowledges the need to maintain its momentum and market share in a competitive landscape, particularly in the inhaled prostacyclins market. This suggests competitive pressures as a risk.
Clinical and Product Development Risks: The company plans to initiate multiple new studies and expand into additional disease areas. These activities carry inherent risks, including potential delays, failures in clinical trials, or inability to achieve desired outcomes.
Strategic Execution Risks: The company’s growth strategy involves disciplined expansion funded by cash flow from operations. Any misstep in execution could impact financial stability and strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 patient referrals and therapy shipments: As of February 28, 2026, the company has received over 3,600 unique patient referrals and shipped therapy for more than 2,900 patients since the launch of YUTREPIA. The company expects continued growth in patient referrals and therapy shipments, maintaining a robust trajectory.
Market share and patient starts: The company anticipates rising market share and capturing a disproportionate number of new patient starts for inhaled prostacyclins, with steady forward momentum across PAH and PH-ILD indications. New patient prescriptions are expected to remain balanced between the two indications.
Expansion of clinical studies: In 2026, the company plans to initiate multiple new studies, including transitioning patients from oral and inhaled prostacyclin therapies, adjunctive studies with sotatercept, and studies for additional disease areas such as systemic sclerosis-associated Raynaud's phenomenon and PH-COPD.
Advancement of L606 pivotal study: The company plans to advance the next-generation L606 pivotal study, with initiation in multiple territories and enrollment expected to begin in the following quarters.
Financial outlook for 2026 and beyond: The company aims to build a durable franchise with increasing patient preference and projects a clear path towards achieving at least a $1 billion franchise in 2027, with growth expected to continue in subsequent years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Where do you think the 2,900 patient starts for YUTREPIA put you in terms of current market share?
A:Management stated it is hard to give an accurate percent market share from a patient number standpoint due to competitors not disclosing their numbers. However, based on revenue analysis, inhaled treprostinil revenue for Q4 was approximately $550 million, and YUTREPIA accounted for more than 100% of market growth in Q4. Their revenue share increased from 10% in Q3 to 17% in Q4.
Q:What is your take on the potential impact of a new addition to the oral prostacyclin receptor agonist mix on the YUTREPIA launch?
A:Management believes the new addition will not have any impact on YUTREPIA. They compared it to UPTRAVI, stating both have similar potency and target binding profiles. They noted muted effects on symptom improvement and significant GI side effects for the new therapy. They do not see it as a threat to YUTREPIA's business.
Q:Can you help us better understand the differentiation of YUTREPIA relative to a soft mist inhaler (SMI) recently announced by another company?
A:Management stated that the SMI does not provide substantial benefits beyond portability. They emphasized YUTREPIA's advantages, including its low-resistance device, high portability, mitigation of cough, and dosing flexibility. They believe the SMI is essentially a repurposed opportunity with no significant clinical or safety improvements over existing therapies.
Q:Regarding the PAH versus PH-ILD split of patients on YUTREPIA, how do you see that evolving over time?
A:Management noted that the split has moved to a roughly equal distribution between PAH and PH-ILD. They see more growth potential in PH-ILD due to its larger white space opportunity and plan to expand their sales force to penetrate this market further. They expect PH-ILD to become a bigger opportunity in terms of patient numbers over time.
Q:Is the $1 billion revenue target for 2027 achievable, and what gives you confidence in maintaining the current pace?
A:Management is confident in achieving the $1 billion target, citing the $2 billion inhaled treprostinil market, opportunities in the $2 billion oral market, and the white space in PH-ILD. They also highlighted their ability to transition patients from competitive agents and their strong trajectory in patient starts and revenue growth.
Q:Are there any updates on the legal front?
A:Management stated there are no new updates. They remain confident in their arguments and expect an opinion soon, as it has been 9 months since the trial and 7 months since post-trial briefings. They are prepared for any outcome.
Q:What is the current status of payer access and prescription-to-patient start conversion?
A:Management reported an 85% prescription-to-patient start conversion rate, which they consider best-in-class. They continue to work on improving access and providing services to ensure patients can obtain YUTREPIA if desired.
Q:Can you provide color on launch dynamics into the first quarter, including inventory stocking trends and refill rates?
A:Management stated that they have normalized inventory and do not expect significant swings. They reported strong patient starts and referrals in January and February, maintaining the same trajectory as Q4.
Q:What is the rationale for the systemic sclerosis RP program, and what is the path forward?
A:Management highlighted the high prevalence of Raynaud's phenomenon in systemic sclerosis patients and the proven efficacy of prostacyclins in managing ischemic episodes. They plan to initiate a Phase IIa program by the end of the year, leveraging YUTREPIA's tolerability and dosing advantages.
Q:What is the role of inhaled treprostinil in the PAH setting compared to oral prostacyclins?
A:Management believes inhaled treprostinil offers better tolerability and symptomatic benefits compared to oral prostacyclins, which have significant GI side effects and minimal symptomatic improvement. They see a shift in the field towards therapies with better benefit-to-risk profiles, favoring YUTREPIA.
Q:What are the dynamics of prostacyclin transition patients, and what exploratory trials are planned for YUTREPIA?
A:Management reported that 25% of YUTREPIA patients are switches, with most coming from inhaled therapies and some from oral prostacyclins. They plan exploratory trials to guide transitions from oral prostacyclins to YUTREPIA and to demonstrate its hemodynamic benefits. They also aim to transition patients on sotatercept to YUTREPIA.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about current market share in terms of patient numbers, citing a lack of competitor data. They also used vague language when discussing the potential impact of the new oral prostacyclin receptor agonist, speculating on its muted effects without specific data. Additionally, their response to the legal updates lacked clarity on the timeline for an opinion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COPD need
Dr Jeffs
Exposure drive
Jeffs Chief
Liquidia cash
Officer Chief
Officer release
Patient transition
SENSE study
YUTREPIA benefit
YUTREPIA safety
YUTREPIA specialty
advancement generation
area sclerosis
bar YUTREPIA
behavior option
benefit product
care study
cash engine
cash flow
cash generation
category SENSE
category chance
center confidence
class
convenience
depth
expansion
experience
measure
momentum
physician
product profile
product sale
profitability
prostacyclins
referral
standard
trajectory
LQDA Transcript
Liquidia Corporation (LQDA) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary indicates strong financial performance and optimistic future guidance. YUTREPIA's market share increased significantly, and management is confident in achieving a $1 billion revenue target by 2027. Product differentiation and strategic clinical trials are expected to drive growth. Despite some vague responses, the overall sentiment is positive, with no major concerns raised. The lack of market cap data prevents a more nuanced prediction, but the positive outlook suggests a stock price increase in the short term.
Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Liquidia Corporation (LQDA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-19
Liquidia Corporation (LQDA) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call highlights strong YUTREPIA adoption, positive cash flow, and profitability ahead of schedule. Although there are execution and litigation risks, the company's strategic plans and payer coverage expansion indicate growth potential. The Q&A session shows positive sentiment from analysts, with management addressing concerns effectively. Overall, the positive financial performance and market strategy outweigh the potential risks, suggesting a stock price increase.
LQDA Slides
LQDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
